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FORMULATIONS OF MELOXICAM 
 
ABSTRACT:  
The aim of this study was to develop a novel gastro retentiveoral floating in situ gelling system 
for controlled release of Meloxicam. Meloxicam is NSAIDs inhibits cyclooxygenase (COX) 
synthesis having analgesic and antipyretic effects. Four polymer based floating in situ gelling 
systems of Meloxicam were prepared by dissolving varying concentrations of different 
ingredients including sodium alginate, HPMC K100 M, calcium carbonate, sodium citrate. The 
prepared gels were characterized for solution viscosity, pH, gelling capacity, floating lag time, 
floating duration and in-vitro release study. All the formulations showed instant gelation 
maintaining integrity for at least 12 hr.  
The study demonstrated that a stomach specific in-situ gel of Meloxicam could be prepared using 
floating mechanism to increase the residence time of the drug in stomach andimproved 
bioavailability and thus improved patient compliance. 
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INTRODUCTION:  
Gastro-retentive in situ gel forming system provides the controlled drugdelivery within stomach. 
In situ gel formation occurs due to one or combination of different stimuli like pH change, 
temperature modulation and solvent exchange
1
.  
The in situ gel dosage form is a liquid before administration but converts into a gel that floats on 
gastric contents as it comes in contact with it. It consist of a solution of low viscosity that on 
coming in contact with the gastric fluids, undergoes change in polymeric conformation viscous 
gel having density lower than the gastric fluids thus floats on the surface of the gastric fluids
2
.  
This low density gel formation provides gastro retention to prolong the contact time, as well as it 
arrange continuous and slow drug release. To produce sustained release formulation of an oral 
liquid formulation could be successfully augmented substantially through a strategy of liquid in 
situ gelling system
3
. Advantages of in situ gel forming systems includes ease of administration 
and reduced frequency of administration, improved patient complianceand comfort and 
improved bioavailability
4
.  
Furthermore solid dosage forms are associated with swallowing problems for geriatric, pediatrics 
and bedridden patient and chances of accidental burst release
5
. Gastroretentive liquid dosage 
forms i.e. in situ gel formulations may be helpful to overcome these limitations. The oral use of 
liquid pharmaceutical has generally been justified on the basis of ease of administration to those 
individuals who have difficulty swallowing solid dosage forms and better patient compliance
6
. 
Meloxicam is a NSAID belonging to the class of oxicams
7
. Meloxicam inhibits cyclooxygenase 
(COX) synthesis. It has analgesic and antipyretic effect and used in the treatment of rheumatoid 
arthritis, osteoarthritis, dental pain, post-traumatic and post-operative pain, inflammation and 
swelling
8,9
.  
The aim of the present study is to develop in situ gelling gastroretentive formulations of 
meloxicam sustained drug release, ease of administration and patient compliance. 
 
 
 MATERIALS AND METHODS: 
Materials: 
Sodium alginate, calcium carbonate and calcium chloride were supplied by Logus Investment 
Limited (Lagos,Nigeria), Sodium citrate and Methyl paraben were obtained from Honeystones 
Nigeria Limited, Lagos,Nigeria. HPMC K100M and Carbopol 940 weresupplied by Krispine Nig 
Ltd (Nigeria). 
Preparation of in situ gel  
Specified quantity of Meloxicam, Sodium citrate, calcium carbonate, calcium chloride, methyl 
paraben, carbopol 940 and HPMC were weighed accurately.  
Accordingly, in about 30 ml of deionized water, HPMC K100M was allowed to hydrate 
overnight. Meloxicam was then dissolved in the HPMC K100M solution and CaCO3 (gas 
generating agent) was added to it while stirring to facilitate dispersion. Sodium alginate solutions 
were prepared by adding to 60 ml of deionized water containing sodium citrate and calcium 
chloride and heating to 60
0
C while stirring on a heating magnetic stirrer (Finlab, Nigeria Ltd). 
After cooling to below 40
0
C, it was added to the HPMC K100M solution while stirring to 
achieve uniform dispersion. Solution of methy paraben and carbopol 940 wereadded and mixed 
properly. Finally, the formulations were adjusted to volume, filled and stored in amber colored 
bottles until further testswere done
10
. 
 
Table 1: Compostion of Meloxicam floating in situ gel formulations. 
Ingredients Formulation code 
G1 G2 G3 G4 
Meloxicam (mg) 100 100 100 100 
Sodium Alginate (% w/v) 2 2 2 1 
HPMC K100M 
(% w/v) 
0.5 0.6 1 0.8 
Calcium carbonate (% w/v) 1 2 1 2 
Sodium citrate (% w/v) 0.5 0.5 0.5 0.5 
Methyl paraben (% w/v) 0.2 0.4 0.6 0.5 
Calcium chloride(% w/v) 0.15 0.15 0.15 0.15 
Carbopol 940 0.5 - 0.7 - 
Distilled water (up to ml) 50 50 50 50 
 
Evaluation of in situ gel formulations 
1. Determination of pH: 
The pH values of all in situ gel formulations of Meloxicam weremeasured using a calibrated 
digital pH-meter (Ms026, Mon Scientific, Nigeria) at room temperature and results were 
recorded as average of three measurements
11
. 
2. Determination of drug content  
Accurately, 10 mL of formulation containing the equivalent of 250 mg Meloxicam from different 
batches was measured and transferred to 100 mL volumetric flask. To this 50-70 mL of 0.1 N 
HCl was added and sonicated for 30 min. Volume was adjusted to 100 mL. Complete dispersion 
of contents was ensured visually and the dispersion was filtered using Whatman Filter Paper. 
From this solution, 10 mL of sample was withdrawn and diluted to 100 mL with 0.1 N HCl. 
 Contents of metronidazole was measured at maximumabsorbance at 362nm using UV-Visible 
Spectrophotometerat (Biotech eng. UV-9200, UK)
12
. 
3. Gelling capacity of formulations 
An oral in situ gelling gastro retentive formulation should undergorapid sol to gel transition 
when it comes in contact with the gastric fluid. Also to facilitate sustained drug release, the in 
situ formed gel should preserve its integrity without dissolving for a prolonged period of time. 
Accurately measured 10 mL of formulation was added to 100 mL of 0.1N hydrochloric acid 
(HCl, pH 1.2) at 37
○
C in a beaker with mild agitation that avoids breaking of formed gel. The in 
vitro gelling capacity was graded in three categories on the basis of stiffness of formed gel, 
gelation time and time period in which, formed gel remainswithout a change
13
.  
(+) Gels after few minutes, dispersed rapidly 
(++) Gelation immediate remains for few hours  
(+++) Gelation immediate remains for an extended period. 
4. Determination of viscosity: 
Viscosity of the prepared in situ gel formulations of Meloxicamwas determined using a 
rotational viscometer (Finlab Nigeria Ltd). Viscosity was measured at different angular velocities 
(from 20 to 100 rpm) using spindle number 2 at room temperature
14
.  
5. In vitro floating study:  
The in vitro floating study was determined by means of USP dissolution apparatus II (Erweka 
DT 600HH, Germany) having 500 ml of simulated gastric fluid (0.1 N HCl) maintained at 37±1 
0
C with a paddle speed of 50 rpm. Ten milliliters of the prepared in situ gelling formulations 
were withdrawn with disposable syringe and added into the dissolution vessel containing 
simulated gastric fluid. The time the formulation took to emerge on the medium surface (floating 
lag time, FLT) and the time the formulation constantlyfloated on the dissolution medium surface 
(duration of floating, TFT) were recorded
15
. 
6. In vitro drug release study: 
The release rate of Meloxicam from in situ gel formulations was determined using USP 
dissolution testing apparatus type-II at 50 rpm. The dissolution medium was used 900 ml of 0.1 
N HCl, and temperature was maintained at 37
o
C. 5 ml of solution containing the optimum 
quantity of sodium citrate, calcium chloride, in distilled water and loaded with drug was placed 
in petridish which was then float on dissolution media. Gelation was instantaneous on contact 
with simulated gastric fluid. One ml of sample of the solution were removed at pre-determined 
interval for analysis and replace with 1 ml of fresh 0.1N HCl. Thedrug concentration of each 
sample was determined spectrophotometrically at 362nm
16
. 
 
Table 2: Characteristics of in situ gel formulations of Meloxicam 
Code pH % Drug 
content 
Gelling 
capacity 
Viscosity 
(cps) 
Floating 
lag time 
(Sec) 
Floating 
duration  
(hr) 
G1 7.25±0.09 98.26±0.21 +++ 165±0.43 24±0.47 12 
G2 7.48±0.15 97.38±0.17 +++ 192±0.37 22±0.35 13 
G3 7.82±0.32 98.24±0.19 ++ 177±0.62 18±0.27 14 
G4 8.12±0.49 96.43±0.25 + 210±0.55 20±0.08 12 
 
+Poor,   ++ Good,     +++Very good 
 
 
    
Figure : Cumulative in-vitro drug release of in situ gel formulations of Meloxicam 
 
 RESULTS AND DISCUSSION:  
Four different in situ gel formulations of Meloxicam were prepared successfully by means of 
using different polymers and ingredients i.e. sodium alginate, HPMC K100M, calcium 
carbonate, sodium citrate in different ratio. Sodium alginate acts as a gelling agent. The free 
Ca2+ ions gets entrapped in polymeric chains of sodium alginate thereby causing cross linking of 
polymer chains to form matrix structure
17
. This gelation involves the formation of double helical 
junction zones followed by reaggregation of the double helical segments to form a three-
dimensional network by complexation with cations and hydrogen bonding with water. CaCO3 
was incorporated as cross linker and floatingagent
18
. 
The formulations possessed satisfactory pH value ranging from 7.25±0.09 to 8.12±0.49 (table 2) 
which is suitable to maintain the formulations in a liquid state. Aqueous solutions of sodium 
alginate are most stable at pH range of 4–10. Below pH 3, alginic acid is precipitated from the 
alginate solution making the formulation unsightly containing gel and liquid phases
19
. 
In all the formulations, sol-to-gel transition occurred instantaneously at the 
formulation/simulated gastric fluid interface. This instantaneous surface gelation formed an 
enclosing membrane which entrapped the remaining liquid formulation at the center and the gel 
layer expanded to the center apparently due to slow diffusion of H
+
 and Ca
2+
 ions. During 
preliminary tests, the gels tend to ooze when pierced in less than 1 hr of gelation and at the end 
of the test period the gels appeared solid throughout their dimensions. However, though gelation 
occurred instantaneously, the nature of the gels formed wasdependent upon the polymer and 
CaCO3 concentration
20
. 
 Low sodium alginate concentration (G4) formed weak gels (table 2) which would not be able to 
withstand peristaltic waves of the GI tract, and might be propelled to the intestine with stomach 
contents.  Floating characteristics of prepared formulations were assessed in simulated gastric 
fluid (0.1 N HCl). All the formulations remained floating on the surface of the medium for at 
least 12 hr (table 2). This indicates that the formulations could provide a sustained delivery of 
Meloxicam to the absorption window for more than 12 hr as long as the gel was not depleted of 
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 the drug. Therefore, higher polymer concentrations impartedextra strength to the gels to remain 
buoyant at least for 12 hr. 
Higher polymer concentrations shorten the floating lag time taken to float completely over the 
surface of the dissolution medium. This may be due to the higher cross-linking density at higher 
polymer concentrations which could effectively trap the released CO2 bubbles so that density of 
the gel is reduced rapidly to induce buoyancy
21
.  All the in situ gel formulations showed 
significant burst release where approximately, 24-30% of Meloxicam was released within the 
first hr. This burst release may be because of dissolution of drug present at the surface of the 
formed gel that could have been released immediately upon contact with the 0.1N HCl. In 
addition to this, some lag time is required for the release of Ca
2+
 ions from CaCO3 and cross 
linking of the guluronate residues of sodium alginate which plays a major role in the formation 
of barrier gel. The release profiles also depicted that all formulations release 81.56% (G4) or 
more of Meloxicam within the study of 12 hrs. Maximumdrug release was shown by 
formulations of batch G1 (94.38%). 
CONCLUSION:  
In this research work, in situ gel formulations of Meloxicamwere successfully developed and 
optimized stomach specific in situ gels which exhibit a unique combination of floatation and 
ionic gelation for prolonged residence in the stomach. Calcium carbonate added to the 
formulation provides calcium ions and carbon dioxide. Calcium ions, due to ion interactions with 
the polymer, help in gelation. Carbon dioxide entraps in the gel and facilitates buoyancy of the 
gel. The in situ formed gel preserved its integrity without dissolving or eroding for prolonged 
period to facilitate sustained release of drugs locally. The developed formulations met all 
prerequisites to become an in situ gelling floating system, gelled, and floated instantaneously in 
the pH conditions of the stomach. It was observed that the resulting gel remained buoyant for 14 
hr and slowly released Meloxicam during the 12 hr period. It is concluded that Meloxicam could 
be targeted to stomach and be released slowly over a period oftime and can improve 
bioavailability of the drug, dosing frequency and hence patient compliance. 
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